Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.66 |
| ▸ | CA9 | Q16790 | 3/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 2/20 | 0.66 |
| ▸ | ERN1 | O75460 | 4/20 | 0.64 |
| ▸ | PLAU | P00749 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | P4HB | P07237 | 1/20 | 0.55 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
| ▸ | FNTB | P49356 | 1/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30443216 | 1.00 | CA12 (0.66) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL27715902 | 0.91 | CA12 (0.71) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL68931 | 0.89 | CA12 (0.69) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL67941 | 0.89 | CA12 (0.68) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL6434807 | 0.88 | ERN1 (0.61) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL1221576 | 0.87 | TSHR (0.67) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL29410906 | 0.87 | TSHR (0.67) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL1180166 | 0.87 | PLAU (0.61) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL8444075 | 0.86 | ERN1 (0.60) | CA12CA9CA1CA2ERN1 | |
| SCHEMBL514 | 0.86 | CA12 (0.66) | CA12CA9CA1CA2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023233346-A1 | CHOLESTEROL DERIVATIVES AND THEIR USES | PRECISION BIO-THERAPEUTICS S.R.L. (IT) | 2023-12-07 | — | — | WO | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| EP-3823960-B1 | ISOXAZOLE AS FXR RECEPTOR AGONISTS | BAR PHARMACEUTICALS SOC A RESPONSABILITA LIMITATA (IT) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022149617-A1 | COMPOUND LIBRARY | 中外製薬株式会社 | 2022-07-14 | — | — | WO | disclosed |
| US-11332450-B2 | Isoxazole as FXR receptor agonists | BAR PHARMACEUTICALS SOCIETA' A RESPONSABILITA' LIMITATA (IT) | 2022-05-17 | — | — | US | disclosed |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2019-07-11 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2490530-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | The Washington University (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050323-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2011-04-28 | — | — | WO | disclosed |
| US-5977105-A | Compounds | ASTRA PHARMAEUTICALS LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| EP-0865431-A2 | COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997020815-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-06-12 | — | — | WO | disclosed |
| US-5298593-A | Polymerization of ester monomer, aromatic dicarboxylic acid, and oxyaromatic carboxylic acid | MITSUBISHI PETROCHEMICAL COMPANY, LTD. (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0520428-A2 | Method of producing thermotropic liquid crystalline polyester | MITSUBISHI CHEMICAL CORPORATION (JP) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | GPBAR1, CYSLTR1, CYSLTR2 | CA12 4101/4885CA9 4205/4885CA1 2945/4885 |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | CA12 335/4885CA9 205/4885CA1 1322/4885 |
| US-11332450-B2 | Isoxazole as FXR receptor agonists | NR1H4, FXR1, GPBAR1 | CA12 3957/4885CA9 3374/4885CA1 2985/4885 |
| US-20190211045-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | CA12 335/4885CA9 205/4885CA1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.